E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
advanced malignant cancer |
stato avanzato di cancro |
|
E.1.1.1 | Medical condition in easily understood language |
advanced malignant cancer |
stato avanzato di cancro |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.1 |
E.1.2 | Level | SOC |
E.1.2 | Classification code | 10029104 |
E.1.2 | Term | Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The purpose of this study is to determine the effective dose range in patients with advanced cancer, who experience inadequate pain relief even though they are on optimized chronic opioid therapy and on lacking of appetite and malnutrition |
valutare come gli agonisti dei recettori del sistema degli endocannabinoidi ed in particolare i fitocannabinoidi, possano migliorare il quadro clinico della malnutrizione e della cinestesi, principale causa di morte nei pazienti tumorali,frequentemente associata ai tumori in fase avanzata attraverso l’effetto che questi composti possano esercitare sulle citochine pro infiammatorie associate alla malnutrizione per la modulazione che essi hanno sui recettori CB2 presenti sulle cellule del sistema immunitario. |
|
E.2.2 | Secondary objectives of the trial |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• The patient has advanced active cancer for which there is no known curative therapy. • The patient is able (in the investigators opinion) and willing to comply with all study requirements. • The patient has a clinical diagnosis of cancer related pain, which is not wholly alleviated with their current opioid treatment. • The patient is receiving a sustained release (SR) fixed dose of opioid therapy (excluding Methadone). N.B. The opiate therapy must be Step III according to the WHO analgesic ladder. • The patient is willing to continue to take their regular daily baseline opioid regimen (SR) at the same dose, throughout the duration of study. |
Il paziente è in uno stato avanzato di cancro per il quale non ci sono terapie curative. Il paziente è capace e di seguire le regole dello studio Il paziente ha una diagnosi di dolore associato al cancro, che non è completamente coperto dalla terapia con oppioidi valutati con scala VAS Il paziente è malnutrito: BMI <20 kg/m con calo ponderale del 10% nei sei mesi precedenti, La terapia oppiacea deve essere StepIII secondo la scala WHO analgesic ladder nei tre mesi precedenti o 5% nel mese precedente Il paziente continuerà a prendere la dose giornaliera di oppioidi per tutta la durata dello studio Ipofagia Assunzione di cibo rispetto all’abituale valutato con diario nutrizionale e scala VAS |
|
E.4 | Principal exclusion criteria |
• The patient should be excluded from entering study if they have received or are due to receive during the study period; chemotherapy, hormone therapy or radiotherapy, which, in the opinion of the investigator will affect their pain. • Any history or immediate family history of schizophrenia, other psychotic illness, severe personality disorder or other significant psychiatric disorder other than depression associated with their underlying condition. • Any known or suspected history of a diagnosed dependence disorder, current heavy alcohol consumption, current use of an illicit drug or current non prescribed use of any prescription drug. • The patient has poorly controlled epilepsy or recurrent seizures (i.e. at least one year since last seizure). • The patient has experienced myocardial infarction or clinically relevant cardiac dysfunction within the last 12 months or has a cardiac disorder that, in the opinion of the investigator would put the patient at risk of a clinically relevant arrhythmia or myocardial infarction. |
Il paziente deve essere escluso dallo studio se sono programmati cicli di chemioterapia, ormonoterapia o radioterapia, che nell’opinione degli investigatori potrebbero influire sull’esito dello studio. Qualsiasi episodio familiare di schizofrenia, malattia psicotiche, disturbi della personalità o stati depressivi. Qualsiasi storia sospetta disordini da dipendenza da droghe, consumi alcolici elevati,. Il paziente ha avuto nell’anno episodi di epilessia. Il paziente ha avuto negli ultimi 12 mesi episodi di infarto del miocardio che potrebbero secondo gli investigatori mettere a rischio il paziente di episodi di aritmia o infarto del miocardio. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary outcome measure is the IVRS 11-point Numeric Rating Scale pain score (average pain). The primary outcome measure is the IVRS 11-point Numeric Rating Scale pain score (average pain) at time 0,1,2. |
A) IVRS 11- point numeric rating scale pain score B) Scored Patients Generated Global Assessment (PG-SGA) C) Prelievi di sangue all’entrata nello studio al tempo T0, a 30 giorni T1 e a 60 giorni T2 per l’analisi qualitativa e quantitativa delle citochine: IL-1,IL-2, IL-4, IL-6, IL-8, IL-10, IL-12, IFN , TNF |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
The primary outcome measure is the IVRS 11-point Numeric Rating Scale pain score (average pain). The primary outcome measure is the IVRS 11-point Numeric Rating Scale pain score (average pain) at time 0,1,2. |
1. Somministrazione di questionari per la valutazione del dolore e della malnutrizione; 2. Prelievi di sangue all’entrata nello studio al tempo T0, a 30 giorni T1 e a 60 giorni T2 per l’analisi qualitativa e quantitativa delle citochine: IL-1,IL-2, IL-4, IL-6, IL-8, IL-10, IL-12, IFN , TNF |
|
E.5.2 | Secondary end point(s) |
non applicabile |
non è previsto nessun end-point secondario |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | No |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | Yes |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Information not present in EudraCT |
E.8.2.2 | Placebo | Information not present in EudraCT |
E.8.2.3 | Other | Information not present in EudraCT |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.4.1 | Number of sites anticipated in Member State concerned | 1 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 0 |
E.8.9.1 | In the Member State concerned months | 36 |
E.8.9.1 | In the Member State concerned days | 0 |